They are “reliable, business-savvy and responsive” with “strong commercial acumen.” “The team balances both legal and practical needs and guides the client effectively.”
Chambers Asia-Pacific 2021

中文 | English

For nearly 40 years Morrison Foerster has been on the ground advising clients about their most important China-related matters. We were among the first U.S. law firms to establish an office in each of China’s major business centers:

  • Hong Kong (1983; qualified to practice Hong Kong law since 2001)
  • Beijing (1998)
  • Shanghai (2003)

We have more than 50 U.S.-, Hong Kong-, PRC-, and England and Wales-qualified professionals, who work closely with attorneys throughout the firm to deliver calibrated and sound advice to clients.

Our team is consistently ranked for its exceptional legal work throughout China in leading independent directories such as: Chambers Asia Pacific, Legal 500 Asia Pacific, and Bloomberg, among others.

We counsel a wide variety of clients in China on their high-profile investment, finance, and regulatory matters, including many of the world’s largest multinationals and the most substantial and active institutional PRC companies, as well as promising startups in the technology, entertainment, telecommunications, life sciences, energy, clean technology, and renewable energy industries.

Show More


  • Represented Alibaba Group in the acquisition of a 33% stake of Ant Financial, operator of China’s biggest online payment platform by market share.

  • Represented Alibaba Group in relation to Ant Financial’s US$14 billion Series C fundraising, valuing Ant Financial at approximately US$150 billion.

  • Represented SoftBank Vision Fund’s US$11 billion investment in WeWork.

  • Represented SoftBank in connection with the additional US$4.6 billion purchase of Didi shares; we also represented SoftBank as sole counsel in its US$4.6 billion investment in Didi.

  • Represented SoftBank Vision Fund in connection with a US$3 billion investment into Local Services Holding Company, a company established by Alibaba after consolidating the businesses of (the food delivery business owned by Alibaba) and (an affiliate company that focuses on bringing local businesses online by providing payment and other technology services); after such consolidation, the valuation of Local Services Holding Company is over US$30 billion.

  • Represented SoftBank Vision Fund in connection with an investment totaling US$1.5 billion in Chehaoduo, a leading Chinese customer-to-customer auto retail services company that operates Guazi, an e-commerce platform focusing on second-hand car transactions, and Maodou, an e-commerce platform focusing on new car transactions.

  • Represented Walmart in a US$500 million financing and strategic alliance with New Dada, China’s largest localized, on-demand logistics and grocery O2O e-commerce platform; the transaction included a US$320 million investment by Walmart and a new business cooperation agreement.

  • Represented Ally Bridge Group in its equity investment in GRAIL, a company developing a blood test that will detect cancer before symptoms appear in order to increase survival rates as compared to those patients with late-stage diagnoses; the investment, led by our client, raised US$300 million in an oversubscribed Series C financing.

  • Represented Oriente, a Hong Kong-based financial services and technology company, in its US$105 million initial funding round, and a series of recent expansions in Southeast Asia, including two strategic alliances: Cashalo in the Philippines with JG Summit, and Finmas in Indonesia with Sinar Mas.

  • Represented Trusted Doctors (Xingren) in its strategic merger agreement with Tencent Doctorwork. The newly formed venture, which is named Tencent Trusted Doctors, will offer an ecosystem of both online and offline services devoted to leveraging Internet technology to provide high-quality and accessible healthcare service to customers all over the country.

  • Represented C-Bridge Capital’s portfolio company Everest Medicines II in its exclusive collaboration, license, and supply agreement with VenatoRx Pharmaceuticals, to support the development and commercialization of cefepime/VNRX-5133 in Greater China, South Korea, and Southeast Asia.

  • Represented the licensing arm of a French multinational corporation as claimant in a Hong Kong law-governed, Hong Kong-seated HKIAC arbitration with substantial PRC law-governed elements.

  • Represented a Chinese consumer products manufacturer as respondent in a Hong Kong law-governed, Hong Kong-seated ad hoc arbitration with substantial PRC law-governed elements and in subsequent enforcement proceedings in Hong Kong and Israel courts.

  • Represented a global industrial gases company as claimant in a PRC law-governed, Shanghai-seated, Chinese-language CIETAC arbitration.

  • Represented multiple Hong Kong and Chinese clients in high-stakes U.S. litigation proceedings, including civil and criminal trade-secret, and economic espionage litigation, and litigation alleging violations of U.S. state and federal securities laws.

  • Represented multiple multinational and China-based clients in internal and government investigations involving alleged violations of anti-corruption laws, anti-money-laundering laws, accounting fraud, conflicts of interest, and trade compliance issues.

Show More


Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.